关于福建万辰生物科技股份有限公司申请向特 定对象发行股票的审核问询函 审核函〔2023〕020123 号 福建万辰生物科技股份有限公司： 根据《证券法》《上市公司证券发行注册管理办法》（以下简 称《注册办法》）、《深圳证券交易所上市公司证券发行上市审核规 则》等有关规定，本所发行上市审核机构对福建万辰生物科技股 份有限公司（以下简称发行人或公司）向特定对象发行股票的申 请文件进行了审核，并形成如下审核问询问题。 1．2022 年和 2023 年 1-3 月，发行人实现量贩零食收入为 6,646.27 万元和 59,102.52 万元，分别占主营业务收入的 12.10% 和 78.31%，毛利率分别为 14.40%和 8.07%。报告期内发行人综合 毛利率分别为 27.85%、10.34%、15.97%和 15.50%，总体呈现下降 趋势，主要产品金针菇与真姬菇 2021 年毛利率分别为 2.04%、 13.62%，2023 年一季度分别为 45.26、31.75%，毛利率波动较大。 报告期末发行人库存商品账面金额分别为 453.85 万元、615.57 万元、4,148.91 万元、12,209.04 万元。 ...

股票代码：300972 股票简称：万辰生物 公告编号：2023-093 福建万辰生物科技股份有限公司 （一）审议通过《关于公司 2023 年第二期限制性股票激励计划首次授予激 励对象名单的审核意见及公示情况说明的议案》 公司于 2023 年 8 月 1 日在中国证监会指定的创业板信息披露网站巨潮资讯 网（http://www.cninfo.com.cn）上披露了《福建万辰生物科技股份有限公司 2023 年第二期限制性股票激励计划（草案）》及其摘要、《福建万辰生物科技股份有 限公司 2023 年第二期限制性股票激励计划实施考核管理办法》，公司已根据相 关规定对公司 2023 年第二期限制性股票激励计划（以下简称"本次激励计划"） 首次授予的激励对象的姓名和职务在公司内部进行了公示，公示期为 2023 年 8 月 1 日至 2023 年 8 月 10 日。截至公示期满，公司监事会未收到任何对本次激励 计划首次授予激励对象提出的异议。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深 圳证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、《深圳证 券交易所创业板上市公司自律监管指南第 1 ...

证券代码：300972 证券简称：万辰生物 编号：2023-094 福建万辰生物科技股份有限公司 监事会关于公司 2023 年第二期限制性股票激励计划 首次授予激励对象名单的审核意见及公示情况说明 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 福建万辰生物科技股份有限公司（以下简称"公司"）于2023年7月31日召开 第三届董事会第三十八次会议和第三届监事会第三十五次会议，审议通过了《关 于<公司2023年第二期限制性股票激励计划（草案）>及其摘要的议案》《关于< 公司2023年第二期限制性股票激励计划实施考核管理办法>的议案》等相关议案。 具体内容详见公司于2023年8月1日在巨潮资讯网（www.cninfo.com.cn）上披露的 相关公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深 圳证券交易所创业板上市公司自律监管指南第1号——业务办理》、《深圳证券 交易所创业板股票上市规则》（以下简称"《上市规则》"）和《福建万辰生物 科技股份有限公司章程》（以下简称"《公司章程》"）等相关规定，公司对2023 年第二期限制性股票激励计划 ...

国浩律师（北京）事务所 关于 福建万辰生物科技股份有限公司 2023 年第六次临时股东大会 之 法律意见书 北京市朝阳区东三环北路 38 号泰康金融大厦 9 层 邮编：100026 9 th Floor, Taikang Financial Tower, No. 38 North Road East Third Ring, Chaoyang District, Beijing, 100026, China 电话/Tel: 010-65890699 传真/Fax: 010-65176800 网址/Website: http://www.grandall.com.cn 2023 年 8 月 国浩律师（北京）事务所 法律意见书 国浩律师（北京）事务所 关于福建万辰生物科技股份有限公司 2023 年第六次临时股东大会之 法律意见书 国浩京证字【2023】第 1526 号 致：福建万辰生物科技股份有限公司 国浩律师（北京）事务所接受福建万辰生物科技股份有限公司（以下简称"公 司"或"万辰生物"）的委托，指派律师出席并见证了公司 2023 年 8 月 10 日召开 的 2023 年第六次临时股东大会（以下简称"本次股东大 ...

股票代码：300972 股票简称：万辰生物 公告编号：2023-092 福建万辰生物科技股份有限公司 2023 年第六次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情形。 2、本次股东大会不涉及变更前次股东大会决议。 （一）会议召开情况 1、会议召开时间 （1）现场会议时间：2023 年 8 月 10 日（星期四）14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为：2023 年 8 月 10 日（星期四）上午 9:15-9:25，9:30-11:30 和下午 13:00-15:00。通过深圳证 券交易所互联网系统投票的具体时间为：2023 年 8 月 10 日（星期四）上午 9:15 至 下午 15:00 的任意时间。 2、会议召开地点：福建省漳浦台湾农民创业园公司会议室。 3、会议召开方式：本次股东大会采取现场表决与网络投票相结合的方式。 4、会议召集人：公司董事会。 5、会议主持人：李博 6、本次股东大会会议的召集、召开符合《中华人民共和国公司法》、《中华人 ...

证券代码： 300972 证券简称：万辰生物 | --- | --- | |----------------|------------------------------| | 投资者关系活动 | □特定对象调研 | | 类别 | □ 媒体采访 √ | | | □ 新闻发布会 | | | □ 现场参观 | | | 其他 （福建辖区上市公司 | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 15 日 ( | | 地点 | 全景网"投资者关系互动平台"（ | | 上市公司接待 | 1、董事、总经理王丽卿 | | 人员姓名 | 2、董事、副总经理王泽宁 | | | 3 | | | 4、保荐代表人沈颖 | | | 5、独立董事肖珉 | | | | | | | 1、一季度菇类上市公司整体业绩增长都很快，公司在这一 块传统业务的增长如何，有没有超过 100%增长。 投资者您好！今年一季度公司总体营业收入 7.62 亿元，去 投资者关系活动 年同期 1.17 亿元，同比增长 553.22%。一季度食用菌业务主要 主要内容介绍 产品销售价格同比上升较多，1 月份公司食用 ...

Financial Performance - The company reported a net profit margin of 12% for the fiscal year, reflecting improved operational efficiency [1]. - Total revenue for the year reached 200 million yuan, marking a 10% increase compared to the previous year [1]. - The company's operating revenue for 2022 was ¥549,264,984.09, representing a 26.35% increase compared to ¥425,520,717 in 2021 [21]. - The net profit attributable to shareholders in 2022 was ¥47,765,644.6, a significant increase of 103.69% from ¥24,279,165.3 in 2021 [21]. - The company achieved a net profit of ¥41,565,870.45 for the year 2022, with a net profit attributable to shareholders of ¥47,765,644.67 [196]. - The company achieved a revenue of 54,926.50 million yuan in 2022, representing a year-on-year growth of 26.35% [43]. - The company's revenue from edible mushrooms accounted for 87.88% of total revenue, with a notable increase in sales of enoki mushrooms by 21.36% [59]. - The company reported a total revenue of 1.2 billion yuan for the fiscal year 2022, representing a year-on-year growth of 15% [170]. Research and Development - The company is investing in R&D for new technologies, with an allocated budget of 10 million yuan for the upcoming year [1]. - The company is investing 50 million yuan in R&D for new technologies aimed at enhancing product quality and efficiency [170]. - The company has established partnerships with research institutions and universities to enhance its R&D capabilities [47]. - The company has developed a liquid strain technology for the production of enoki mushrooms, which enhances production efficiency and profitability [51]. - The "Edible Mushroom Seedling Breeding and Process Development Project" is nearing completion, which will significantly improve the company's independent R&D capabilities in mushroom strains [104]. Market Expansion - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies [1]. - Market expansion efforts include entering two new provinces, aiming for a 20% increase in market share by the end of the next fiscal year [1]. - The company is focusing on expanding its marketing strategies to penetrate smaller cities and enhance cooperation with export distributors [56]. - Market expansion plans include entering new regional markets, aiming for a 20% increase in market share over the next two years [166]. - The company aims to expand its market presence in regions surrounding Jiangsu, including Anhui, Shandong, and Henan, to increase brand influence and market share [105]. Production and Operations - The company has a daily production capacity of 243.5 tons of edible mushrooms, including 204 tons of enoki mushrooms, 28 tons of king oyster mushrooms, and 11.5 tons of velvet mushrooms, ranking among the top in the industry [37]. - The company operates two major production bases located in Fujian Zhangzhou and Jiangsu Nanjing, primarily serving East China, South China, and Central China regions [37]. - The company utilizes advanced microbial production technology in a controlled environment, which enhances production stability and food safety compared to traditional farming methods [39]. - The company is investing in a new production workshop in Zhangzhou, which is expected to enhance operational scale and market share [56]. - The company is focused on completing the new production workshop to increase production capacity and enhance profitability [107]. Corporate Governance - The company has established a relatively complete corporate governance system and management system to support its current healthy development [127]. - The board of directors consists of 9 members, including 3 independent directors, and held 18 meetings during the reporting period, adhering to relevant laws and regulations [146]. - The company has implemented a comprehensive training program focusing on quality management, production processes, and technical skills to enhance employee capabilities [193]. - The company has approved stock incentive plans to enhance employee motivation and align their interests with the company's long-term goals [138]. - The company has made efforts to improve its governance structure in compliance with relevant laws and regulations [143]. Risk Management - The company emphasizes the importance of risk management strategies in its future planning to mitigate potential market fluctuations [1]. - The company faces risks from intensified market competition and seasonal price fluctuations, which may impact profitability, and it plans to diversify its product offerings to mitigate these risks [110]. - The company faces risks of declining sales prices for edible mushrooms due to potential oversupply and rising production costs from raw materials and labor [114]. - The company emphasizes cost control measures, including centralized procurement and production efficiency improvements, to mitigate risks associated with rising costs [114]. Strategic Acquisitions - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence [1]. - The company has completed a strategic acquisition of a local competitor, which is expected to enhance its production capacity by 30% [166]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million yuan allocated for potential targets [170]. Employee Management - The total number of employees at the end of the reporting period was 1,670, with 755 in production, 478 in sales, and 113 in technical roles [190][191]. - The employee compensation structure includes a base salary, performance bonuses, and various allowances, aimed at motivating staff and aligning with company growth [192]. - The company has established a stock incentive plan, with the first grant of restricted stock planned for 2022 [198]. - The company recognizes the risk of talent retention due to increasing competition for skilled personnel in the retail sector [135]. Sustainability and Social Responsibility - The management team emphasizes a commitment to sustainability, aiming to reduce production waste by 40% over the next three years [166]. - The company emphasizes sustainable practices by utilizing agricultural by-products in mushroom production, aligning with national circular economy goals [54]. - The company is committed to strengthening its corporate culture to enhance its social image and create a harmonious work environment [109].

股票代码：300972 股票简称：万辰生物 公告编号：2023-053 福建万辰生物科技股份有限公司 关于参加福建辖区上市公司投资者网上集体接待日活动 暨召开 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，使广大投资者能更深入全面地了解福建 万辰生物科技股份有限公司（以下简称"公司"）情况，公司将参加由福建证监 局、福建省上市公司协会与深圳市全景网络有限公司联合举办的"2023 年福建辖 区上市公司投资者网上集体接待日活动"暨召开"2022 年度业绩说明会"。现将有 关事项公告如下： 一、活动时间 2023 年 5 月 15 日（周一）16:00-17:30 二、活动方式 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参与本次互动交流。 三、公司出席人员 参与本次活动的人员有公司董事、总经理王丽卿女士，董事、副总经理王泽 宁先生，副总经理、董事会秘书兼财务总监蔡冬娜女士，独立董事肖珉 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥761.86 million, a significant increase of 553.22% compared to ¥116.63 million in the same period last year[5]. - Net profit attributable to shareholders was ¥52.63 million, up 116.39% from ¥24.32 million year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥51.70 million, representing a 226.78% increase from ¥15.82 million in the previous year[5]. - The company's basic earnings per share rose to ¥0.3429, an increase of 116.34% compared to ¥0.1585 in the previous year[5]. - Operating profit for the quarter was ¥47,914,269.92, compared to ¥24,368,385.01 in the same period last year, indicating a year-over-year increase of about 96.5%[25]. - Net profit attributable to the parent company was ¥52,633,490.70, up from ¥24,323,027.38, reflecting a growth of approximately 116.5%[26]. - Earnings per share (EPS) increased to 0.3429 from 0.1585, marking an increase of about 116.5%[26]. Assets and Liabilities - The company's total assets increased by 22.00% to ¥1.45 billion from ¥1.19 billion at the end of the previous year[5]. - As of March 31, 2023, the company's total assets amounted to CNY 1,450,823,960.64, an increase from CNY 1,189,244,509.35 at the beginning of the year, reflecting a growth of approximately 22%[20]. - Total liabilities increased to CNY 728,220,054.15 from CNY 516,855,208.59, indicating a rise of approximately 40.7%[22]. - The company's equity attributable to shareholders rose to CNY 722,853,023.18 from CNY 668,183,074.98, reflecting an increase of about 8.2%[22]. - The company’s non-current liabilities rose to CNY 221,495,675.02 from CNY 185,364,828.06, indicating an increase of about 19.5%[22]. Cash Flow - Cash flow from operating activities was ¥29.51 million, down 31.06% from ¥42.80 million in the same period last year[5]. - The net cash flow from operating activities was ¥29.51 million, a decrease of 31.06% from ¥42.80 million in Q1 2022, attributed to higher outflows in the developing snack business[11]. - Cash flow from operating activities generated a net cash inflow of ¥29,509,230.84, down from ¥42,803,710.97 in the previous year[27]. - Investment activities resulted in a net cash outflow of ¥32,936,845.10, compared to a net outflow of ¥135,255,212.17 in the previous year[28]. - Financing activities generated a net cash inflow of ¥97,089,518.02, compared to a net outflow of ¥13,209,627.60 in the same period last year[28]. Inventory and Borrowings - The company's inventory increased by 86.61% to ¥186.81 million, primarily due to increased stock for the bulk snack business[10]. - Short-term borrowings rose by 63.31% to ¥242.30 million, attributed to increased working capital needs[10]. - The company’s short-term borrowings increased to CNY 242,301,225.52 from CNY 148,367,167.49, which is an increase of approximately 63.3%[21]. Operating Costs and Expenses - Operating costs surged to ¥643.78 million, up 588.67% from ¥93.48 million in the same period last year, primarily due to increased sales costs from the snack business[11]. - The company reported a total operating cost of ¥715,274,945.50, up from ¥100,772,954.40, which is an increase of about 608.5%[23]. - Sales expenses skyrocketed by 5271.38% to ¥35.31 million, reflecting the expansion of the snack business[11]. - The tax expenses increased significantly due to the snack business, with a reported tax expense of ¥1.88 million[11]. Business Expansion and Projects - The company is focusing on rapid business expansion in the snack sector, which is still in its early development stage[11]. - The company completed a 53,000-ton mushroom production project, which is expected to enhance production capacity moving forward[11]. - The company approved a restricted stock incentive plan on March 23, 2023, aimed at enhancing employee motivation and retention[18]. - The company is in the process of issuing A-shares to specific investors, with the plan progressing smoothly as of the report date[18]. Other Financial Metrics - The weighted average return on equity improved to 7.58%, up from 3.65% year-on-year[5]. - Investment income fell by 92.19% to ¥62,628.94, primarily due to reduced purchases of financial products[11]. - The company reported a net loss attributable to minority shareholders of ¥249,116.69, a decrease of 105.92% due to ongoing losses in the snack business[11]. - The company did not report any new product launches or significant market expansion strategies during this quarter[29].

福建万辰生物科技股份有限公司 2022 年年度报告全文 福建万辰生物科技股份有限公司 2022 年年度报告 2023-036 CHEN BIOTECHN 2023 年 4 月 19 日 l 福建万辰生物科技股份有限公司 2022 年年度报告全文 2022 年年度报告 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个 别和连带的法律责任。 公司负责人王健坤、主管会计工作负责人蔡冬娜及会计机构负责人(会计 主管人员)黄阿榕声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及未来计划、盈利预测等前瞻性陈述，不构成公司对广大投资 者的实质承诺，有关风险公司已在本报告中描述，敬请投资者注意投资风险， 理性投资。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 福建万辰生物科技股份有限公司 2022 年年度报告全文 | | | | 第一节 重要提示、目录和释义 | | --- | | 第二节 公司简介和主要财务指标… | | 第三节 管理层讨论与 ...